Drug Search Results
More Filters [+]

Moxifloxacin

Alternative Names: moxifloxacin, avelox, vigamox, moxeza
Latest Update: 2024-05-13
Latest Update Note: Clinical Trial Update

Product Description

Moxifloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat and prevent plague (including pneumonic and septicemic plague). Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. (Sourced from: https://www.mayoclinic.org/drugs-supplements/moxifloxacin-oral-route/side-effects/drg-20072313?p=1)

Mechanisms of Action: HERG Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Plague | Pneumonia, Bacterial | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Chlamydia Infections | Conjunctivitis, Bacterial | Corynebacterium Infections | Escherichia coli Infections | Haemophilus Infections | Klebsiella Infections | Pneumonia, Bacterial | Trachoma | Conjunctivitis | Pneumonia | Influenza, Human

Known Adverse Events: Bradycardia | Myocardial Ischemia | Dizziness | Headache | Myasthenia Gravis | Drug Hypersensitivity | Hypersensitivity, Immediate | Nut Hypersensitivity | Central Nervous System Bacterial Infections | Plague | Pneumonia, Bacterial | Muscle Weakness | Hypokalemia | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Asthenia | Diarrhea | Conjunctivitis

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Moxifloxacin

Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, France, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, South Africa, Spain, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 25

Highest Development Phases

Phase 3: COVID-19|Capsule Opacification|Cataract|Conjunctivitis, Bacterial|Endophthalmitis|Fractures, Open|Influenza, Human|Otitis Externa|Otitis Media|Pneumonia|Pneumonia, Bacterial

Phase 2: Tuberculosis, Pulmonary

Phase 1: Cystic Fibrosis|Healthy Volunteers|Hypertension|Multiple Sclerosis|Muscular Dystrophy, Becker|Muscular Dystrophy, Duchenne|Obesity|Overweight|Pain Unspecified|Scleroderma, General

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PARADIGM4TB

P2

Recruiting

Tuberculosis, Pulmonary

2027-02-24

REMAP-CAP

P3

Recruiting

Pneumonia|COVID-19|Influenza, Human

2026-02-01

DURATIOM

P3

Not yet recruiting

Fractures, Open

2026-01-31

PIND 134134

P3

Not yet recruiting

Endophthalmitis|Capsule Opacification|Cataract

2025-10-01

69%

Recent News Events